Retatrutide vs Tirzepatide vs Semaglutide: Mounjaro, Ozempic, Zepbound & Wegovy Compared

Retatrutide, tirzepatide (Mounjaro/Zepbound), and semaglutide (Ozempic/Wegovy) represent three generations of incretin-based weight loss and diabetes drugs. Each targets a different number of hormone receptors, and each has produced progressively larger weight loss results in clinical trials. This comparison is sometimes framed as GLP-3 vs GLP-1 — referring to the triple agonist (retatrutide) versus the single agonist (semaglutide) — though "GLP-3" is an informal nickname, not a scientific term.

Here is the short version: semaglutide activates one receptor, tirzepatide activates two, and retatrutide activates three. In trials, that progression has translated to roughly 15%, 22%, and 29% body weight loss, respectively. But the details matter — trial designs differ, retatrutide is not yet approved, and no head-to-head study has compared all three directly.

This page breaks down the comparison with data from the published trials, along with the caveats you need to interpret that data fairly.

Side-by-Side Comparison

How the Mechanisms Differ: Single vs Dual vs Triple Agonism

All three drugs belong to the same family — they mimic gut hormones called incretins to regulate appetite, blood sugar, and metabolism. The difference is how many hormone receptors each drug activates.

Semaglutide: GLP-1 Only

Semaglutide targets a single receptor: GLP-1. This reduces appetite, slows gastric emptying (so you feel full longer), and improves insulin secretion. GLP-1 agonism is the foundation of this entire drug class and remains highly effective on its own.

Tirzepatide: GLP-1 + GIP

Tirzepatide adds a second target: GIP (glucose-dependent insulinotropic polypeptide). GIP complements GLP-1 by further stimulating insulin release and may have additional effects on fat metabolism. In head-to-head trials, tirzepatide outperformed semaglutide for both weight loss and blood sugar control.

Retatrutide: GLP-1 + GIP + Glucagon

Retatrutide adds a third receptor: glucagon. This is the key differentiator. While GLP-1 and GIP primarily work by reducing how much you eat, the glucagon receptor increases how much energy your body burns — through thermogenesis (heat production) and lipolysis (fat breakdown). Retatrutide is the first drug to attack obesity from both sides of the energy balance equation: reduced intake and increased expenditure.

For a deeper explanation of each receptor, see What Is Retatrutide (GLP-3)?.

Weight Loss Comparison

This is what most people want to know. Here are the headline numbers from the pivotal trials of each drug.

Peak Weight Loss by Drug

*TRIUMPH-4 enrolled participants with obesity and knee osteoarthritis specifically.

Weight Loss Thresholds (Percentage of Participants Achieving Each Level)

The threshold data for retatrutide TRIUMPH-4 was reported at the 25% and 30% levels, reflecting the higher overall weight loss in this trial. Direct threshold-to-threshold comparisons with semaglutide and tirzepatide should be made cautiously — see the caveats section below.

Why You Cannot Directly Compare These Numbers

These are not results from a single head-to-head study. Each number comes from a different trial, with different:

• Populations: STEP 1 and SURMOUNT-1 enrolled general obesity populations. TRIUMPH-4 enrolled people with obesity and knee osteoarthritis.
• Durations: 48 weeks (Phase 2 retatrutide), 68 weeks (STEP 1, TRIUMPH-4), 72 weeks (SURMOUNT-1).
• Trial phases: Phase 2 trials are smaller and often produce more favorable results than Phase 3 trials.
• Sample sizes: The Phase 2 retatrutide trial had 338 participants versus 1,961 (STEP 1) and 2,539 (SURMOUNT-1).
• Placebo responses: Placebo weight loss varied across trials.
• Baseline characteristics: Starting weight, age, and comorbidities differed.

The general trend — more receptors, more weight loss — is clear. But the precise difference between the drugs can only be determined by a head-to-head randomized controlled trial, and none comparing all three has been conducted.

Diabetes Management Comparison

All three drugs significantly reduce HbA1c (a measure of average blood sugar over 2-3 months) in people with type 2 diabetes.

Tirzepatide currently has the strongest published HbA1c data. Retatrutide's diabetes data is limited to Phase 2 results — larger Phase 3 diabetes-specific trials are expected to clarify where it stands.

One important nuance: retatrutide's glucagon receptor activation raises blood sugar in isolation. In the context of the triple agonist, the GLP-1 and GIP components more than compensate, and the net effect is still significant glucose reduction. But this is an area researchers are watching closely.

Side Effects Comparison

The side effect profiles of all three drugs are broadly similar, dominated by gastrointestinal (GI) symptoms. This is expected — GLP-1 agonism slows gastric emptying, and GI symptoms are the main tolerability issue across the entire drug class.

Common Side Effects

For all three drugs, GI side effects are most common during dose escalation and tend to improve over time. The gradual dose-titration protocols used in clinical trials are specifically designed to minimize these effects.

Notable Differences

• Semaglutide has the longest real-world safety track record, with millions of patients treated since 2017.
• Tirzepatide has a growing real-world safety profile since 2022 and has been generally well-tolerated.
• Retatrutide has shown a dysesthesia signal — a tingling, burning, or prickling sensation on the skin — that was observed in Phase 2 trials and appears to be related to glucagon receptor activation. This is a side effect not typically seen with semaglutide or tirzepatide and warrants monitoring in Phase 3 data.

For more detail on retatrutide's safety profile, see Side Effects & Safety.

Unique Advantages of Each Drug

Semaglutide

• Longest track record: Approved since 2017, with extensive real-world data and post-marketing surveillance.
• Oral option available: Rybelsus (for diabetes) and oral Wegovy (for obesity) offer a non-injectable alternative — the only incretin drug with an oral formulation.
• Broadest insurance coverage: More insurers cover semaglutide than tirzepatide, and coverage will likely exceed retatrutide for years after its launch.
• Cardiovascular outcomes data: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events — a benefit not yet proven for tirzepatide or retatrutide.

Tirzepatide

• Stronger weight loss than semaglutide: Consistently produces greater weight loss in trials, including in head-to-head comparisons.
• Superior HbA1c reduction: The strongest blood sugar control data among approved drugs.
• Available now: Unlike retatrutide, tirzepatide is approved and accessible through standard prescriptions and programs like LillyDirect.
• Growing real-world evidence: Over two years of post-approval data supporting its efficacy and safety.

Retatrutide

• Greatest weight loss observed: 28.7% in TRIUMPH-4 — the largest weight loss result for any anti-obesity medication in clinical trials.
• Liver fat reduction: Phase 2 data showed an 81-86% reduction in liver fat, dramatically outperforming semaglutide and tirzepatide. This has significant implications for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
• Increased energy expenditure: The glucagon receptor component increases the rate at which the body burns calories, a mechanism unique among the three drugs.
• Potential for osteoarthritis benefit: TRIUMPH-4 demonstrated significant pain relief in participants with knee osteoarthritis.

Liver Fat: Retatrutide's Standout Data Point

One area where retatrutide clearly differentiates itself is liver fat reduction. In the Phase 2 trial, retatrutide at the 12 mg dose reduced liver fat by 81-86% over 48 weeks. For context:

• Semaglutide reduces liver fat by approximately 40-50% in studies.
• Tirzepatide has shown liver fat reductions of approximately 50-55% in the SYNERGY-NASH trial.

This dramatic difference is attributed to the glucagon receptor. Glucagon directly promotes fat oxidation in the liver, reducing both fat accumulation and inflammation. This makes retatrutide a particularly promising candidate for people with MASH/NAFLD — a condition that currently has very limited treatment options.

The Phase 3 TRIUMPH program includes a dedicated MASH trial, and results are expected to further define this potential advantage.

Availability and Access

If you are currently interested in incretin-based weight loss treatment, semaglutide and tirzepatide are your options. Retatrutide is not available outside of clinical trials. Be cautious of any online source claiming to sell retatrutide — these are unregulated, unverified, and potentially dangerous.

For more on retatrutide's path to market, see FDA Approval Timeline.

For information on anticipated pricing and access once approved, see Cost & How to Get It.

Cost Comparison

Insurance coverage varies significantly by plan and indication (diabetes vs. obesity). Many insurers cover these drugs for type 2 diabetes but not for weight loss alone, though coverage for obesity indications has been expanding.

Who Might Benefit from Each

These are general considerations, not medical recommendations. Your doctor is the right person to determine which drug is appropriate for you.

Semaglutide may be a good fit if you:

• Want the most established drug with the longest safety track record
• Prefer an oral option (no injections)
• Have cardiovascular risk factors (SELECT trial showed cardiovascular benefit)
• Need broad insurance coverage
• Are looking for a moderate level of weight loss (~15%)

Tirzepatide may be a good fit if you:

• Want stronger weight loss than semaglutide offers
• Have type 2 diabetes and want the best available HbA1c reduction
• Are comfortable with injectable treatment
• Want an approved drug available today with a strong efficacy profile

Retatrutide may be worth watching if you:

• Have significant liver fat or MASH/NAFLD
• Are interested in the most potent weight loss option once it becomes available
• Have not achieved sufficient results with semaglutide or tirzepatide
• Are willing to wait for FDA approval (expected 2027) or consider clinical trial enrollment

Important Caveats About Comparing Trial Data

This deserves its own section because the comparison numbers are often cited without context.

1. No head-to-head trial exists. The only fair way to compare drugs is in a randomized controlled trial where participants are randomly assigned to each drug under identical conditions. That trial has not been conducted for these three drugs.

2. Phase 2 vs Phase 3 matters. Retatrutide's widely-cited 24.2% figure comes from a Phase 2 trial with 338 participants over 48 weeks. Phase 2 trials are smaller and often produce more optimistic results. The Phase 3 TRIUMPH-4 result of 28.7% at 68 weeks is more robust but was conducted in an osteoarthritis population.

3. Different populations, different results. STEP 1 and SURMOUNT-1 enrolled general obesity populations. TRIUMPH-4 enrolled people with obesity and knee osteoarthritis. Population differences affect outcomes.

4. The weight loss curve may not have plateaued. In the Phase 2 retatrutide trial, participants were still losing weight at 48 weeks — the curve had not flattened. This suggests the final weight loss ceiling may be even higher, but it also means the 48-week number is not a final result.

5. Efficacy in trials does not guarantee real-world results. Clinical trial participants receive close monitoring, regular check-ins, and structured support. Real-world adherence is typically lower, and results may be more modest.

6. Individual variation is substantial. Within every trial, some participants lose significantly more than average and some lose less. The "average" result may not reflect your personal outcome.

Frequently Asked Questions

Sources

• Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. The Lancet. DOI: 10.1016/S0140-6736(23)01053-X
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
• ClinicalTrials.gov: NCT04881760, NCT04867785

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. The clinical trial data cited on this page reflects results from controlled research settings and may not reflect real-world outcomes.

If you are considering weight loss medication, talk to your doctor about currently approved options. For information about enrolling in retatrutide clinical trials, visit ClinicalTrials.gov.

This site is not affiliated with Eli Lilly and Company, Novo Nordisk, or any pharmaceutical manufacturer.